Provider Briefing: Clorazepate Availability in 2026

If your patients are reporting difficulty filling Clorazepate (Tranxene) prescriptions, the issue is real — and it's not new. Clorazepate Dipotassium, a long-acting benzodiazepine with FDA-approved indications for anxiety disorders, partial seizures (adjunctive), and acute alcohol withdrawal, has faced persistent availability challenges driven by a limited manufacturer base and low market demand relative to other benzodiazepines.

This briefing covers the current supply landscape, clinical implications for your prescribing decisions, and practical resources to help your patients maintain access to treatment.

Timeline: How We Got Here

Clorazepate has experienced intermittent availability issues for several years:

• Historical context: Tranxene (brand) was originally marketed by Abbott Laboratories and later transferred to Recordati Rare Diseases Inc. Over time, generic competition remained limited, with only a few manufacturers producing the drug.
• 2020-2024: Broader pharmaceutical supply chain disruptions affected many medications, including less commonly prescribed benzodiazepines. While Clorazepate was not formally listed on FDA shortage databases during most of this period, patients and pharmacies reported inconsistent availability.
• Early 2026: ANI Pharmaceuticals received FDA approval for a new generic Clorazepate Dipotassium tablet (ANDA), adding a meaningful new supply source. The U.S. market for Clorazepate is estimated at approximately $25.8 million annually.

Prescribing Implications

The availability situation creates several clinical considerations:

Continuity of Care

Patients on stable Clorazepate regimens who cannot fill their prescriptions face real risk. Abrupt benzodiazepine discontinuation can precipitate:

• Rebound anxiety or insomnia
• Withdrawal seizures (potentially life-threatening)
• Autonomic instability
• Psychotic symptoms in severe cases

Given nordiazepam's long half-life (~40-50 hours), patients may have a slightly wider window before withdrawal onset compared to shorter-acting agents, but this should not create complacency. Proactive planning is essential.

Dose Equivalency for Switching

If transitioning patients to an alternative benzodiazepine, standard equivalency estimates are:

• Clorazepate 7.5 mg ≈ Diazepam 5 mg
• Clorazepate 7.5 mg ≈ Lorazepam 0.5-1 mg
• Clorazepate 7.5 mg ≈ Clonazepam 0.25-0.5 mg
• Clorazepate 7.5 mg ≈ Chlordiazepoxide 12.5 mg

These are approximate equivalencies. Individual patient response varies, and cross-tapering is recommended over abrupt switches when clinically feasible.

Alternative Agents

The most clinically appropriate alternatives depend on the indication:

• For anxiety: Diazepam, Lorazepam, Chlordiazepoxide, or non-benzodiazepine options (SSRIs, SNRIs, Buspirone)
• For seizures (adjunctive): Clonazepam, Clobazam (Onfi), or broader anticonvulsant options (Levetiracetam, Lamotrigine)
• For alcohol withdrawal: Chlordiazepoxide, Diazepam, Lorazepam (particularly in hepatic impairment due to simpler metabolism)

Current Availability Picture

As of March 2026:

• FDA shortage status: Clorazepate is not listed on the FDA Drug Shortage Database
• ASHP shortage status: Not currently listed as an active shortage
• Real-world availability: Inconsistent. Many chain pharmacies do not routinely stock Clorazepate. Independent pharmacies and mail-order pharmacies tend to have better access.
• New generic: ANI Pharmaceuticals' generic entry should improve availability as distribution scales up

Cost and Access Considerations

Cost barriers may compound availability issues for your patients:

• Cash price: $29-$155 per 30 tablets (7.5 mg) without insurance
• With discount coupons (GoodRx, SingleCare): $29-$34 per 30 tablets
• Insurance: Generally covered as Tier 2 or Tier 3 generic. Some plans may require prior authorization for benzodiazepines or impose quantity limits.
• Patient assistance: Prescription Hope offers Tranxene at $50/month for qualifying patients. NeedyMeds and RxAssist list additional resources.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps locate pharmacies with Clorazepate in stock. This can be integrated into your workflow when patients report fill difficulties — rather than asking patients to make a dozen phone calls, you can direct them to a single resource.

Pharmacy Communication

A direct call from a prescriber's office to a pharmacy can sometimes expedite special orders or transfers. Consider designating staff to manage medication availability issues proactively, particularly for patients on benzodiazepines or other controlled substances with supply constraints.

Documentation

When switching patients due to availability (rather than clinical preference), document the reason in the chart. This protects both you and the patient if questions arise from insurers or during continuity-of-care transitions.

Looking Ahead

The addition of ANI Pharmaceuticals as a generic manufacturer is the most significant positive development for Clorazepate supply in recent years. As their product enters distribution channels, availability should gradually improve. However, given Clorazepate's relatively small market size, supply may remain less robust than for higher-volume benzodiazepines.

For providers managing patients on Clorazepate, the key strategies remain:

1. Proactive refill planning (recommend patients request refills 7-10 days early)
2. Familiarity with dose-equivalent alternatives
3. Use of tools like Medfinder for Providers to assist patients in locating stock
4. Clear documentation when availability forces therapeutic changes

For patient-facing information to share, see our companion article: Clorazepate shortage update for patients. For guidance on helping patients locate their medication, see how to help your patients find Clorazepate in stock.